CRISPR treatment frees kids from lifelong blood transfusions

NCT ID NCT05356195

First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 24 times

Summary

This study tests a one-time gene-editing treatment (CTX001) in 16 children with transfusion-dependent beta-thalassemia, a severe blood disorder. The therapy uses the child's own stem cells, modified with CRISPR-Cas9, to produce healthy red blood cells. The main goal is to see if children can stop needing regular blood transfusions for at least 12 months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOGLOBINOPATHIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Great Ormond Street Hospital for Children

    London, United Kingdom

  • Hospital for Sick Children - Hematology

    Toronto, Canada

  • IRCSS Ospedale Pediatrico Bambino Gesu - Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica

    Rome, Italy

  • St.Mary's Hospital - Children's Clinical Research Facility

    London, United Kingdom

  • TriStar Medical Group Children's Specialists - Pediatric Oncology

    Nashville, Tennessee, 37203, United States

  • University Hospital Dusseldorf - Department of Pediatric Oncology, Hematology and Clinical Immunology

    Düsseldorf, Germany

Conditions

Explore the condition pages connected to this study.